Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Dec;5(1):40.
doi: 10.1186/s40169-016-0121-6. Epub 2016 Oct 20.

Clinical Study of Gene-Eden-VIR/Novirin in Genital Herpes: Suppressive Treatment Safely Decreases the Duration of Outbreaks in Both Severe and Mild Cases

Affiliations
Free PMC article

Clinical Study of Gene-Eden-VIR/Novirin in Genital Herpes: Suppressive Treatment Safely Decreases the Duration of Outbreaks in Both Severe and Mild Cases

Hanan Polansky et al. Clin Transl Med. .
Free PMC article

Expression of concern in

Abstract

Background: We conducted a clinical study that tested the effect of suppressive treatment with the botanical product Gene-Eden-VIR/Novirin on genital herpes. Our previous paper showed that the treatment decreased the number of genital herpes outbreaks without any side effects. It also showed that the clinical effects of Gene-Eden-VIR/Novirin are mostly better than those reported in the studies that tested acyclovir, valacyclovir, and famciclovir. The current paper reports the effect of suppressive treatment with Gene-Eden-VIR/Novirin on the duration of outbreaks, in severe and mild genital herpes cases.

Methods: The framework was a retrospective chart review. The population included 137 participants. The treatment was 1-4 capsules per day. The duration of treatment was 2-48 months. The study included three controls: baseline, no-treatment, and dose-response.

Results: The treatment decreased the duration of outbreaks in 87 % of participants and decreased the mean duration of outbreaks from 8.77 days and 6.7 days in the control groups to 2.87 days in the treatment group (P < 0.001, both groups). All participants reported no adverse experiences.

Conclusions: This paper shows that suppressive treatment with Gene-Eden-VIR/Novirin decreased the duration of genital herpes outbreaks, in both severe and mild cases, without any side effects. Based on the results reported in this and our previous paper, we recommend suppressive treatment with Gene-Eden-VIR/Novirin as a natural alternative to both suppressive and episodic treatments with current drugs, in both severe and mild genital herpes cases. Trial registration ClinicalTrials.gov NCT02715752 Registered 17 March 2016 Retrospectively Registered.

Keywords: Acyclovir; Famciclovir; Genital herpes; Natural treatment; Outbreaks; Valacyclovir.

Figures

Fig. 1
Fig. 1
Graph showing the percentage of participants versus duration of outbreaks in the treatment, pre-treatment and no-treatment groups

Similar articles

See all similar articles

Cited by 3 articles

References

    1. Chosidow O, Drouault Y, Leconte-Veyriac F, et al. Famciclovir vs. aciclovir in immunocompetent patients with recurrent genital herpes infections: a parallel-group, randomized, double-blind clinical trial. Br J Dermatol. 2001;144(4):818–824. doi: 10.1046/j.1365-2133.2001.04139.x. - DOI - PubMed
    1. LeCleach L, Trinquart L, Do G, et al. Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients. Cochrane Database Syst Rev. 2014;8:CD009036. - PubMed
    1. Kimberlin DW, Rouse DJ. Clinical practice. Genital herpes. N Engl J Med. 2004;350(19):1970–1977. doi: 10.1056/NEJMcp023065. - DOI - PubMed
    1. Johnston C, Corey L. Current concepts for genital Herpes Simplex Virus Infection: diagnostics and pathogenesis of genital tract shedding. Clin Microbiol Rev. 2016;29(1):149–161. doi: 10.1128/CMR.00043-15. - DOI - PMC - PubMed
    1. Lebrun-Vignes B, Bouzamondo A, Dupuy A, Guillaume JC, Lechat P, Chosidow O. A meta-analysis to assess the efficacy of oral antiviral treatment to prevent genital herpes outbreaks. J Am Acad Dermatol. 2007;57(2):238–246. doi: 10.1016/j.jaad.2007.02.008. - DOI - PubMed

Associated data

LinkOut - more resources

Feedback